ENDRA Life Sciences Inc
NASDAQ:NDRA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
ENDRA Life Sciences Inc
Stock-Based Compensation
ENDRA Life Sciences Inc
Stock-Based Compensation Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Stock-Based Compensation | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
ENDRA Life Sciences Inc
NASDAQ:NDRA
|
Stock-Based Compensation
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Stock-Based Compensation
$299m
|
CAGR 3-Years
11%
|
CAGR 5-Years
12%
|
CAGR 10-Years
11%
|
|
|
Stryker Corp
NYSE:SYK
|
Stock-Based Compensation
$243m
|
CAGR 3-Years
13%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Stock-Based Compensation
$664m
|
CAGR 3-Years
0%
|
CAGR 5-Years
2%
|
CAGR 10-Years
8%
|
|
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
Stock-Based Compensation
$60m
|
CAGR 3-Years
6%
|
CAGR 5-Years
14%
|
CAGR 10-Years
12%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Stock-Based Compensation
$788.2m
|
CAGR 3-Years
15%
|
CAGR 5-Years
15%
|
CAGR 10-Years
17%
|
|
ENDRA Life Sciences Inc
Glance View
ENDRA Life Sciences, Inc. develops medical imaging technology. The company is headquartered in Ann Arbor, Michigan and currently employs 22 full-time employees. The company went IPO on 2017-06-28. The firm has developed a technology platform, Thermo Acoustic Enhanced Ultrasound (TAEUS), which is intended to enhance the capability of clinical ultrasound technology and support the diagnosis and treatment of various other medical conditions. Its TAEUS technology platform application focuses on quantifying fat in the liver and stage progression of non-alcoholic fatty liver disease (NAFLD), which untreated, can progress to Non-alcoholic Steatohepatitis (NASH), fibrosis, cirrhosis, and liver cancer. The firm's TAEUS platform has various clinical applications, such as tissue composition, temperature monitoring, vascular imaging, and tissue perfusion.
